MEDTRONIC MICRA TRANSCATHETER PACEMAKER SYSTEM
Medtronic, Inc. · Decision date Apr 6, 2016
What did the FDA approve?
FDA approved Medtronic's Micra Transcatheter Pacemaker System, Pacemaker Model MC1VR01 with Programmer Application Software model SW022 Version 1.1, on April 6, 2016. The approval covers the leadless pacemaker for patients with symptomatic paroxysmal or permanent high-grade AV block in the presence of atrial fibrillation, or in the absence of AF when atrial lead placement is considered difficult, high risk, or not deemed necessary for effective therapy.
The indication also includes symptomatic bradycardia-tachycardia syndrome or sinus node dysfunction, including sinus bradycardia or sinus pauses, as an alternative to atrial or dual chamber pacing under the same atrial lead placement conditions. Rate-responsive pacing is indicated to provide increased heart rate appropriate to increasing levels of activity. The statement reports the device's intended use; it does not independently establish safety or clinical effectiveness.
FDA approval order statement
Approval for the Micra Transcatheter Pacemaker System (Pacemaker Model MC1VR01 and Programmer Application Software model SW022 Version 1.1). This device is indicated for use in patients who have experienced one or more of the following conditions: symptomatic paroxysmal or permanent high-grade AV block in the presence of AF symptomatic paroxysmal or permanent high-grade AV block in the absence of AF, as an alternative to dual chamber pacing, when atrial lead placement is considered difficult, high risk, or not deemed necessary for effective therapy symptomatic bradycardia-tachycardia syndrome or sinus node dysfunction (sinus bradycardia or sinus pauses), as an alternative to atrial or dual chamber pacing, when atrial lead placement is considered difficult, high risk, or not deemed necessary for effective therapyRate-responsive pacing is indicated to provide increased heart rate appropriate to increasing levels of activity.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 6, 2016
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150033
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic, Inc.
- Product code
- PNJ
- Decision code
- APPR
- Decision date
- Apr 6, 2016
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Leadless pacemaker.
- Applicant
- Medtronic, Inc.
- Product code
- PNJ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P150033 received
Application receipt date recorded by FDA.
P150033 · FDA decision
APPR
P150033/S230 · Related supplement
Micra Functional Testing on pNGHT and NGHT
Timeline entries are records held by MedtechLedger for P150033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Micra Functional Testing on pNGHT and NGHTP150033/S230 | Medtronic, Inc. | PMA supplement | Sep 8, 2026 | FDA |
Explore the linked device profile
Other records with product code PNJ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AVEIR VR Real-World Evidence StudyP150035/S042 | ABBOTT MEDICAL | PMA supplement | Oct 21, 2026 | FDA |
Aveir VR Leadless SystemP150035 | ABBOTT MEDICAL | PMA approval | Mar 31, 2022 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P150033
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

